Alexandra Glucksmann, Ph.D., Chief Operating Officer at Editas Medicine Inc.
Alexandra Glucksmann is Chief Operating Officer and founding employee at Editas Medicine Inc., a gene editing company whose mission is to translate its genome editing technology into a novel class of human therapeutics. Previously, Alexandra was Senior Vice President of Research and Development at Cerulean Pharma, which she joined at its founding. Cerulean Pharma is a clinical-stage company developing innovative nanopharmaceutical tumor-targeting products. Prior to joining Cerulean in 2006, she spent 13 years at Millennium Pharmaceuticals which she joined in 1993 as one of its first scientists. At Millennium, she held a series of science positions with increasing responsibility, ultimately becoming Vice President of all platform technology groups before moving into a senior role in strategic program management and operations. She serves on the board of Women in the Enterprise of Science and Technology (WEST). Alexandra was a post-doctoral fellow at the Massachusetts Institute of Technology and holds a Ph.D. with honors from the University of Chicago.
LINKS
Background
Ms. Alexandra Glucksmann, PhD. has been Chief Operating Officer at Editas Medicine Inc. since April 2015. Prior to joining Editas Medicine, she served as Senior Vice President of Research and Business Operations at Cerulean Pharma Inc. (formerly, Tempo Pharmaceuticals Inc.) There, she was a founding employee and key contributor to all aspects of building the company, including setting strategy, analyzing product development opportunities, cultivating platform and product
Alexandra joined Editas Medicine in November 2013 and is the Chief Operating Officer. Prior
to joining Editas Medicine, Alexandra was senior vice president of
research and business operations from 2006 until June 2013 at Cerulean
Pharma, a clinical-stage company developing innovative
nanopharmaceutical tumor-targeting products. There, she was a founding
employee and key contributor to all aspects of building the company,
including setting strategy, analyzing product development opportunities,
cultivating platform and product partnership prospects, and
participating in fundraising activities. Prior to joining Cerulean in
2006, Alexandra spent 13 years at Millennium Pharmaceuticals, which she
joined in 1993 as one of its first scientists. At Millennium, she held a
series of positions with increasing responsibility and was critical in
helping Millennium evolve from a genomics research-focused organization
to a fully integrated pharmaceuticals company with marketed products.
Her division played an integral role in Millennium’s numerous large
pharma collaborations, which generated more than $1.8 billion in funding
for the company. She serves as the chairperson of the Board of
Directors of Women Entrepreneurs in Science and Technology (WEST).
Alexandra was a post-doctoral fellow at the
Massachusetts Institute of Technology and holds a Ph.D. with honors from
the University of Chicago and a B.S. in molecular biology from the
University of Wisconsin.
Experience
COO
Editas Medicine
Board of Directors
Taconic
Senior VP Research and Development
Cerulean Pharma
Senior VP Research & Business Operation
Cerulean Pharma
(Formerly named Tempo Pharmaceuticals)
From Scientist to VP
Millennium Pharmaceuticals
Education
MIT
Post-doctoral fellow
University of Chicago
PhD Molecular Genetics and Cell Biology
////////////
No comments:
Post a Comment